Holen Sie sich die Stockscreener-App
214.29
2.55%
5.33
Handel nachbörslich:
214.29
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$208.96
Offen:
$208.58
24-Stunden-Volumen:
1.32M
Relative Volume:
0.89
Marktkapitalisierung:
$31.08B
Einnahmen:
$5.54B
Nettoeinkommen (Verlust:
$1.52B
KGV:
20.66
EPS:
10.3734
Netto-Cashflow:
$1.74B
1W Leistung:
+11.08%
1M Leistung:
+7.99%
6M Leistung:
-16.82%
1J Leistung:
-22.83%
1-Tages-Spanne:
$207.78
$215.20
1-Wochen-Bereich:
$190.21
$215.20
52-Wochen-Spanne:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
214.29 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
353.10 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
168.40 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
69.65 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
40.08 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | JP Morgan | Overweight |
| 2025-12-16 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Down 31%: Is there any chance of a rebound from ResMed shares? - The Motley Fool Australia
Is It Too Late to Buy ResMed Inc (RMD) After 4.0% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
ResMed Inc. (RMD) Stock Analysis: Exploring a 27% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Resmed Inc (RMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Resmed Inc (RMD) Institutional Confidence - TradingKey
ResMed (ASX:RMD) Dividend Outlook: What Income Investors Are Watching? - Kalkine
Resmed Inc (RMD) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed stock steadies as sleep-apnea demand supports earnings and growth - AD HOC NEWS
Resmed Inc (RMD) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed Inc. (RMD) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Resmed Inc (RMD) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
Resmed Inc (RMD) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (RMD) Earnings Dates, Call Summary & Reports - TipRanks
RESMED INC. R (RMEA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance
ResMed stock advances on its latest earnings backdrop. - AD HOC NEWS
Resmed Inc (RMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
J.P. Morgan Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
Catapult Sports, Hazer Group & ResMed - marketscreener.com
Resmed Inc (0KW4) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
ResMed stock trades near recent lows as investors assess obesity drug impact and earnings momentum - Ad-hoc-news.de
Resmed Inc (0KW4) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2026 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Resmed Inc (0KW4) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Same Industry, Less Money: What Boston Scientific and ResMed Offer That Abbott Laboratories Does Not - Trefis
ResMed (ASX:RMD) Moves Lower Today — Is the Sleep Apnoea Giant Still Worth Watching? - Kalkine
Canaccord Genuity Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed stock steadies as investors weigh sleep apnea demand and recent earnings - Ad-hoc-news.de
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion - TIKR.com
ResMed stock steadies as sleep apnea demand supports earnings growth - Ad-hoc-news.de
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says - Moomoo
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE - marketscreener.com
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE:RMD) - TradingView
ResMed stock trades near record territory as sleep apnea demand drives revenue growth - Ad-hoc-news.de
UBS lowers ResMed stock price target to $300 on valuation - Investing.com UK
UBS lowers ResMed stock price target to $300 on valuation By Investing.com - Investing.com Nigeria
ResMed stock trades near recent highs as sleep apnea demand supports growth - Ad-hoc-news.de
Can ResMed (ASX:RMD) Reignite Growth by Slimming Down? - Kalkine Media
ResMed sharpens focus with a strategic sale: The Shift Few Are Watching - Kalkine Media
ResMed Target Price Cut 10% to A$40.00/Share by Canaccord Genuity>RMD.AU - Moomoo
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief Australia: EQ Resources, ResMed Inc, BHP Group Ltd and more - Smartkarma
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Resmed Inc-Aktie (RMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Jul 07 '26 |
Sale |
218.55 |
4,991 |
1,090,771 |
466,223 |
1.06%
0.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):